Merck & Co's New Shingles Vaccine Clears First Phase III Hurdle
Executive Summary
Merck & Co has positive data from the first of two Phase III trials of its new varicella zoster virus vaccine for the prevention of shingles in immunocompromised patients, but will the product be enough to prop up its waning Zostavax in the face of GSK's Shingrix?
You may also be interested in...
New Anti-CMV Therapies Post-Transplant: Merck & Co Leads The Pack
Merck & Co’s investigational anti-CMV therapy letermovir is expected to be filed for approval later this year and could be the first of a new generation of anti-CMV therapies, following top-line Phase III data showing it reduced all-cause mortality in bone marrow transplant patients.
GSK's Shingles Vaccine Steps Closer To Catching Zostavax
GlaxoSmithKline is preparing for major filings next year for its challenger to Sanofi Pasteur MSD's Zostavax shingles vaccine, now named Shingrix (HZ/su vaccine), after promising top-line data in a second Phase III trial confirmed its benefits in an older patient population.
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.